Red biotechnology involves the application of biotechnology in the production of biopharmaceuticals and pharmaceuticals. Biotechnology is increasingly gaining prominence in medicine over the last few years. The global biotechnology market is gaining from evolution of the healthcare industry to provide advanced diagnostics and novel line of treatment for medical conditions. Red biotechnology aka medical biotechnology involves the development of novel therapeutic procedures and advanced diagnostics. The application of biotechnology in pharmaceutical and biopharmaceutical segments involve examination of cells and tissues, stem cells, orphan drugs, pharmacogenetics, genetic testing, gene therapy, and proteomics. Red biotechnology is primarily used for neurosciences and protein research.
The application of biotechnology in pharmaceuticals has helped the healthcare industry discover line of treatment for almost 5,000 to 8,000 rare diseases that affect almost 27 to 63 million people worldwide, which represents 6-8% of the global population. Red biotechnology has also helped for the diagnosis and treatment of an array of life-threatening diseases. Furthermore, advances in biotechnology for pharmaceutical and biopharmaceutical industry have improved treatment efficacy considerably. For instance, the application of red biotechnology in the pharmaceutical industry have improved survival rate of most cancers.
Currently, North America holds supremacy in the global red biotechnology market followed by Europe. North America typically is a pioneer in the introduction of new products and is an early adopter of integration of advanced sciences for public welfare. Europe also exhibits strong hold in the global red biotechnology market. Emerging economies in Asia Pacific, Latin America, and the Middle East and Africa are anticipated to emerge as lucrative markets for red biotechnology in the upcoming years, owing to the need for affordable treatment for several diseases and rising healthcare expenditure in these regions. Red biotechnology is the application of biotechnology in biopharmaceuticals and pharmaceuticals production. It provides patients with innovative and modern modes of diagnostics and treatments. This biotechnological application involves research and study on cells and tissues, genetic testing, stem cells, gene therapy, orphan drugs, proteomics and pharmacogenetics. The red biotechnology mainly focuses on neurosciences and protein research.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2063
Some of the major factors driving the global market for red biotechnology include breakthrough outcome of new medical therapies, increase in use of biocatalysis process in the synthesis and production of active pharmaceutical ingredients, advancements in biopharmaceuticals, increasing consumer awareness and government initiatives. However, high capital investment and technical limitations may pose a challenge to the growth of red biotechnology market. Some of the market players in this industry include Amgen, Inc., Beijing Tiantan Biological Products Co., Ltd., Biogen Idec, Inc., Cephalon, Inc., Chiron Corporation, CSL Limited, Genentech, Inc., Genzyme Corporation, Gilead Sciences, Inc., MedImmune LLC, Serono SA and Shenyang Sunshine Pharmaceutical Co., Ltd.